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Introduction
Myelin is a multilamellar, tightly compacted membrane that 
surrounds axons in the central nervous system (CNS) and 
  peripheral nervous system (PNS). Myelin helps concentrate 
 voltage-gated  Na
+ channels at nodes of Ranvier (Pedraza et al., 
2001), the short unmyelinated regions between myelin seg-
ments. The nerve impulse jumps from node to node by a process 
called saltatory conduction, which facilitates rapid nerve com-
munication in an energy-effi  cient manner. Although mamma-
lian CNS and PNS myelin serve similar functions, they can be 
distinguished by two major features. First, oligodendrocytes 
form multiple myelin internodes in the CNS, whereas Schwann 
cells form single myelin internodes in the PNS. Second, myelin 
proteolipid protein (PLP), a four-transmembrane-domain pro-
tein, represents >50% of the protein in mammalian CNS mye-
lin (Milner et al., 1985), whereas P0 protein, a type I integral 
membrane glycoprotein and member of the immunoglobulin 
gene super family, represents >70% of the total myelin protein 
in mammalian PNS myelin (Lemke and Axel, 1985).
P0 was initially the primary structural protein of CNS and 
PNS myelin, which fi  rst appeared  440 million years ago in 
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cartilaginous fi  sh (Waehneldt et al., 1986; Kirschner et al., 1989; 
Saavedra et al., 1989; Waehneldt, 1990; Yoshida and Colman, 
1996). The DM20 isoform of the Plp gene also appeared in car-
tilaginous fi  sh myelin, where it was apparently coopted by du-
plication of an ancestral gene (DMα family) that originated in 
Drosophila melanogaster (Stecca et al., 2000) and is expressed 
today in neurons and epithelial cells (Kitagawa et al., 1993). 
The PLP protein appeared after the divergence of the bony fi  sh 
 400 million years ago (Yoshida and Colman, 1996) and dif-
fers from DM20 by the addition of 35 amino acids into exon III 
(Macklin et al., 1987; Nave et al., 1987). Both PLP and P0 had 
high mutational rates until  300 million years ago. During this 
period, it is likely that the function of PLP was evolving, with a 
requirement for the continued coexpression of P0. However, 
with the appearance of reptiles/aves, the function of PLP 
became fully established, allowing the silent dropout of P0 from 
CNS myelin (Waehneldt, 1990; Yoshida and Colman, 1996). 
Once PLP and P0 expression was separated exclusively into 
CNS and PNS myelin, their mutation rates dropped dramati-
cally, and both are highly conserved (almost 100%) across all 
mammalian species analyzed (Kurihara et al., 1997; Hudson, 
2004; Kirschner et al., 2004). This suggests an essential role for 
PLP and/or a detrimental role for P0 protein in CNS myelin of 
higher species.
Myelin also provides trophic support, which is essen-
tial for axonal survival. Axonal degeneration is the major 
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T
he central nervous system (CNS) of terrestrial verte-
brates underwent a prominent molecular change 
when a tetraspan membrane protein, myelin proteo-
lipid protein (PLP), replaced the type I integral membrane 
protein, P0, as the major protein of myelin. To investigate 
possible reasons for this molecular switch, we genetically 
engineered mice to express P0 instead of PLP in CNS myelin. 
In the absence of PLP, the ancestral P0 provided a periodic-
ity to mouse compact CNS myelin that was identical to 
mouse PNS myelin, where P0 is the major structural pro-
tein today. The PLP–P0 shift resulted in reduced myelin in-
ternode length, degeneration of myelinated axons, severe 
neurological disability, and a 50% reduction in lifespan. 
Mice with equal amounts of P0 and PLP in CNS myelin had 
a normal lifespan and no axonal degeneration. These 
data support the hypothesis that the P0–PLP shift during 
vertebrate evolution provided a vital neuroprotective func-
tion to myelin-forming CNS glia.T
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cause of neurological disability associated with inherited 
and acquired diseases of myelin (Scherer, 1999; Trapp 
et al., 1999).
Although the molecular mechanisms responsible for this 
trophic support are not well understood, mice with a null mu-
tation in the Plp gene have a late-onset axonopathy (Griffi  ths 
et al., 1998). It remains to be determined whether this axo-
nopathy results from loss of PLP-related trophic support or 
from alterations in the periodicity and/or stability of PLP-
 defi  cient myelin. In addition, mutation and duplication of the 
human PLP gene is a major cause of the inherited disease of 
myelin, Pelizaeus-Merzbacher disease. To investigate the pos-
sible benefi  ts for the P0–PLP evolutionary conversion, we 
  “reversed” that evolutionary step using transgenic mice and 
introduced P0 expression in exchange for PLP into the mam-
malian CNS. In the absence of PLP, P0 protein conferred a 
highly regular and compact PNS-like structure to CNS  myelin. 
However, because of degeneration of myelinated axons, the 
lifespan of these mice (compared with wild-type [WT] or 
PLP-null mice) was reduced by >50%. Based on these data, 
reversing a discrete step in vertebrate brain evolution demon-
strates that the emergence of a new myelin protein was associ-
ated with a vital neuroprotective function of myelin-forming 
CNS glia.
Results
Generation and molecular characterization 
of mice
Technically, the preferred strategy for expressing P0 and remov-
ing PLP is a direct knockout and knockin of genes by homolo-
gous recombination in ES cells. However, when the full-length 
cDNA encoding P0 was placed in-frame into exon 2 of the Plp 
gene, mutant mice expressed very little P0 mRNA, presumably 
because of the altered spacing of cis-regulatory elements. 
Therefore we chose to cross mice carrying a P0 transgene, 
strongly expressed in oligodendrocytes, on a Plp-null back-
ground. We generated transgenic mice in which the mammalian 
P0 cDNA was driven by 9.1 Kb of the murine myelin basic pro-
tein (MBP) promoter (Forghani et al., 2001). These mice were 
bred to mice null for PLP (Klugmann et al., 1997). The hetero-
zygous F1 pups were interbred to generate pups that were geno-
typed for PLP and the P0 transgene. The resulting pups were 
genotyped and interbred further, and at the F3 generation, mice 
were identifi  ed to be WT, PLP-null, P0 homozygous transgenic 
(PLP/P0-CNS), and P0 homozygous transgenic plus PLP-null 
(P0-CNS; Fig. 1 A). Two lines of mice homozygous for the 
P0 transgene were generated, and neither showed a neurological 
phenotype. The changes described below in mice homozygous 
Figure 1.  Replacement of PLP with P0. (A) PCR (P) and Southern blot (S) 
analysis of genomic-tail DNA from WT, P0-CNS, PLP/P0-CNS, and 
PLP-null mice. The diagnostic PCR product for the PLP-null mice was 
620 bp in length. The diagnostic band for the P0 transgene was 1.8 kb. 
(B) Northern blot analysis of P0 or PLP mRNA expression in WT, P0-CNS, 
PLP/P0-CNS, and PLP-null mice. P0 mRNA is present in P0-CNS and 
PLP/P0-CNS; PLP mRNA is present in WT and PLP/P0-CNS. Neither 
mRNA is detected in PLP-null CNS. (C) Polyacrylamide gel electropho-
resis analysis of myelin proteins from WT, P0-CNS, PLP/P0-CNS, and 
PLP-null mice and WT sciatic nerve. Equivalent amounts of P0 and PLP are 
present in myelin isolated from PLP/P0-CNS mice. Note the presence of 
P0 and the absence of PLP in myelin from P0-CNS mice. (D) Western blot 
of myelin fractions from WT, P0-CNS, PLP/P0-CNS, and PLP-null mice. 
P0 protein is present in PLP/P0-CNS and P0-CNS myelin; PLP is detected in 
WT and PLP/P0-CNS myelin. The   genetic manipulations had little effect 
on levels of MAG, CNP, or MBP.
Figure 2.  CNS distribution of PLP and P0 protein. (A–D) PLP protein 
was detected immunocytochemically in WT (A) and PLP/P0-CNS (C) 
CNS but not in PLP-null (B) and P0-CNS (D) CNS. P0 protein was de-
tected in PLP/P0-CNS (G) and P0-CNS (H) CNS but not in WT (E) or 
PLP-null (F) CNS. Where present, the general distributions of PLP and 
P0 were similar and reﬂ  ected the overall pattern of myelin distribution 
in P30 mouse brain. At the ultrastructural level, P0 was not detected 
immuno  cytochemically in WT (I) or PLP-null (J) CNS myelin but was 
abundant in compact CNS myelin in PLP/P0-CNS (K) and P0-CNS (L) 
mice. Bars: (A–H) 200 μm; (I–L) 200 nm.T
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for the P0 transgene and null for PLP are therefore not caused by 
insertional mutagenesis.
These four mouse lines were maintained and included in 
the present study. To determine whether the genotypes translate 
to the mRNA level, total brain RNA was isolated from all four 
lines at postnatal day (P) 60 and probed with P0 and PLP 
cDNAs by Northern blot (Fig. 1 B). These data establish that the 
P0 transgene is abundantly transcribed in the CNS and that mice 
null for PLP mRNA express signifi  cant levels of P0 mRNA.
Myelin was also prepared from P60 brains, and its protein 
composition was analyzed on SDS gels (Fig. 1 C). As expected, 
WT CNS myelin contained PLP, myelin from PLP/P0-CNS 
mice contained P0 and PLP, P0-CNS myelin contained P0, and 
PLP-null mice contained neither P0 nor PLP. The levels of P0 
and PLP were similar in the PLP/P0-CNS myelin, and the level 
of P0 in the P0-CNS myelin appeared similar to PLP in WT 
  myelin. Our goal of replacing PLP with similar levels of P0 was 
therefore achieved. We also compared levels of three other my-
elin proteins, myelin-associated glycoprotein (MAG), 2′, 
3′-  cyclic nucleotide 3′-phoshodiesterase (CNP), and MBP in 
CNS myelin purifi  ed from the four lines of mice by Western 
blot (Fig. 1 D). There were no signifi  cant differences in levels of 
these myelin proteins except their increase in PLP-null myelin, 
which refl  ects their relative contribution to total myelin proteins 
after the loss of PLP, i.e., 50% of the total myelin protein.
We next determined the cellular distribution of P0 and 
PLP in the different mice by immunocytochemistry (Fig. 2). 
P0 protein was synthesized by oligodendrocytes in P0-CNS and 
PLP/P0-CNS mice and targeted to myelin internodes. At the light 
microscopic level, the distribution of P0 (Fig. 2, G and H) was 
indistinguishable from PLP in WT (Fig. 2 A) or PLP/P0-CNS 
(Fig. 2 C) brains. To determine whether P0 was targeted to 
compact myelin, we performed electron microscopic immuno-
cytochemistry using immunogold procedures (Fig. 2, I–L). 
P0 was not detected in compact myelin from WT (Fig. 2 I) or 
PLP-null (Fig. 2 J) mice but was abundant in PLP/P0-CNS 
(Fig. 2 K) and P0-CNS (Fig. 2 L) compact myelin. When ex-
pressed, P0 protein did not accumulate in mouse oligodendro-
cyte perinuclear cytoplasm, nor was it targeted to paranodal 
loops or oligodendrocyte plasma membranes. Similar to their 
amphibian ancestors, mammalian oligodendrocytes maintain 
their ability to appropriately and exclusively target P0 to 
compact myelin.
P0 stabilizes compact CNS myelin
To investigate the possible impact of P0 protein on the periodic-
ity or membrane spacing of CNS myelin, we analyzed optic 
nerves from the mice by x-ray diffraction and transmission EM. 
X-ray diffraction measures myelin periodicity and membrane 
packing of unfi  xed, freshly dissected nerves. As documented 
previously (Schmitt et al., 1941), typical CNS and PNS myelin 
diffraction patterns are readily distinguished from one another 
by the spacing between refl  ections (which signals the periodic-
ity) and by the number of refl  ections. Thus, for WT animals, 
CNS myelin shows two strong Bragg orders (the second and 
fourth) from an  155-Å periodicity, whereas PNS myelin 
shows four distinctive Bragg orders (the second through fi  fth) 
from an  174-Å periodicity (Kirschner and Blaurock, 1992). 
Figure 3.  X-ray diffraction patterns and EM 
of transgenic and WT compact myelin. (A) The 
diffraction pattern of P0-CNS optic nerve mye-
lin (red) is similar to that of WT sciatic nerve 
myelin (black) in period (174 Å) and relative 
intensities of the small-angle region (Bragg 
  orders 1–5) and the wide-angle region (inset, 
enlarged, with Bragg orders 7, 8, and 11). 
Note that compared with sciatic, the optic 
nerve had a smaller peak intensity to back-
ground, indicating less myelin. (B) Diffractions 
from WT optic nerve myelin (black) and optic 
nerve myelin containing P0 and PLP (PLP/
P0-CNS; purple) have identical 155-Å periods 
and relative intensities (Bragg orders 2–4). 
X-ray scatter from the PLP knockout (PLP-null; 
green) shows a very weak pattern with ex-
panded arrays of membranes. The positions of 
the Bragg orders in A and B are marked by 
the arrowheads. (C and D) Membrane proﬁ  les 
calculated for the diffraction data shown in A 
and B. Electron density on a relative scale is 
plotted as a function of radial distance (in ang-
stroms) from the center of a cytoplasmic appo-
sition. There is close correspondence in the 
intermembrane spaces, measured as the dis-
tance between electron-dense peaks, for my-
elin from P0-CNS optic nerve and WT sciatic 
(C) and for optic nerves PLP/P0-CNS and WT 
(D). The periodicity and apposition of extra-
cellular (EC) and   cytoplasmic (CYT) membrane 
leaﬂ  ets is shown for WT myelin from PNS (C) and optic nerve (D). In contrast, PLP-null optic nerve had a much larger extracellular space between membranes 
and a 194-Å period. In transmission electron micrographs, the periodicity of P0-CNS myelin (E) is identical to WT PNS myelin (F). The periodicity of PLP/ 
P0-CNS myelin (G) is identical to WT CNS myelin (H). Bar, 20 nm.JCB • VOLUME 172 • NUMBER 3 • 2006  472
Optic nerves from P0-CNS mice gave a diffraction pattern that 
was identical to WT sciatic nerve; i.e., the positions of the re-
fl  ections and the relative intensities were the same (Fig. 3 A). 
This was true even for the higher resolution region of the pat-
terns, where higher Bragg orders were detected (Fig. 3 A, inset). 
The membrane profi  les (Fig. 3 C) that were calculated from the 
diffraction data showed similar dimensions: as measured from 
the positions of the centers of the electron-dense peaks, the 
membrane bilayers were  47 Å wide, the cytoplasmic apposi-
tions were  32 Å wide, and the extracellular spaces were  48 Å 
wide. The only signifi  cant difference between the myelin dif-
fraction from WT sciatic and P0-CNS optic nerves was the over-
all stronger intensity of the WT sciatic nerve. This difference 
refl  ects thicker myelin internodes (more lamellae) in the PNS 
than in the CNS.
For optic nerves from PLP/P0-CNS mice, the diffraction 
patterns were virtually identical to WT CNS myelin (Fig. 3 B), 
i.e., with the second and fourth Bragg orders being the strongest 
and located at positions corresponding to a 155-Å periodicity. 
The membrane profi  les calculated from these patterns showed 
similar dimensions, with  47-Å-wide bilayers,  32-Å-wide 
cytoplasmic spaces, and  32-Å-wide extracellular spaces 
(Fig. 3 D). Thus, despite its known homophilic interactions in 
trans (D’Urso et al., 1990; Filbin et al., 1990), P0 appeared to 
have little affect on myelin spacing when expressed at equal 
amounts with PLP. The x-ray scatter recorded from PLP-null 
optic nerves (Fig. 3 B) indicated expanded arrays of disordered 
membranes, with a 194-Å periodicity compared with the 155-Å 
period of WT optic nerve myelin. Consistent with the diffrac-
tion data, electron micrographs showed that the periodicity of 
compact myelin in P0-CNS optic nerves (Fig. 3 E) was identical 
to compact myelin in WT sciatic nerves (Fig. 3 F) and greater 
than that of compact myelin in WT optic nerves (Fig. 3 G) or 
PLP/P0-CNS optic nerves (Fig. 3 H).
Neurological disability and mortality
To determine the effect of replacing PLP with P0 on motor func-
tion, we compared the performance of P0-CNS mice on a stan-
dard rota-rod treadmill with that of WT, PLP/P0-CNS, or 
PLP-null mice at 3, 6, and 12 mo of age (Fig. 4 A). At 3 mo of 
age, all strains of mice performed similarly. At 6 mo of age, the 
performance of WT, PLP/P0-CNS, and PLP-null mice was in-
distinguishable, whereas that of the P0-CNS mice was reduced 
by 70%. Compared with WT mice at 12 mo of age, the perfor-
mance of P0-CNS and PLP-null mice was reduced by 90 and 
60%, respectively, whereas the performance of PLP/P0-CNS 
mice was unchanged. We terminated these experiments at 12 mo 
of age because of the high mortality rate of the P0-CNS mice.
The mortality rate of P0-CNS mice was compared with 
that of WT, PLP/P0-CNS, and PLP-null mice (Fig. 4 B). There 
was no difference in the mortality rate of WT, PLP/P0-CNS, and 
PLP-null mice. The mortality rate of P0-CNS mice, how-
ever, was signifi  cantly increased. Approximately 50% of the 
P0-CNS mice died by 12 mo of age. 80% were dead by 16 mo, 
and none lived past 18 mo, when 70% of the other strains were 
still surviving. Thus, replacing PLP with P0 in mouse CNS 
myelin causes the premature death of these mice.
Axonal pathology and degeneration
The reduced lifespan of P0-CNS mice and the earlier demon-
stration of axonal pathology in PLP-null mice (Griffi  ths et al., 
1998) prompted histological examination of the P0-CNS mice 
for underlying neurodegenerative changes. We performed a de-
tailed analysis of the amyloid precursor protein (APP) in the 
brains from the four lines of mice. APP detection is a reliable 
indicator of axonal pathology in primary myelin disease affect-
ing PLP-null mice (Griffi  ths et al., 1998; Edgar et al., 2004) and 
humans with multiple sclerosis (Ferguson et al., 1997). APP is 
only detected in axons with compromised axonal transport (Koo 
et al., 1990). A dramatic increase in APP immunoreactivity 
  occurred in the P0-CNS brains compared with the brains from 
the other three lines (Figs. 5, A–D). This APP immunoreactivity 
appeared predominately as small ovoids. This is consistent with 
previous identifi  cation of APP accumulation in axonal swell-
ings (Griffi  ths et al., 1998; Edgar et al., 2004). We quantifi  ed 
APP-positive ovoid densities in the cerebral cortex from 1-, 
3-, 6-, and 12-mo-old mice. WT (Fig. 5 A) and PLP/P0-CNS 
(Fig. 5 C) mice contained few APP-positive swellings. In contrast, 
Figure 4.  Reduced motor performance and increased mortality in P0-CNS mice. (A) Analysis of standard rota-rod test of mice at 3, 6, and 12 mo of age. 
Rota-rod performance was similar for all four strains of mice at 3 mo of age. At 6 mo of age, motor performance was signiﬁ  cantly reduced in P0-CNS mice 
and similar in the other lines. At 12 mo of age, performance of P0-CNS mice worsened and performance of PLP-null mice was signiﬁ  cantly reduced when 
compared with WT and PLP/P0-CNS mice (*, P < 0.0001; **, P < 0.001). (B) Kaplan-Meier curve assessing survival as a function of age for the four 
lines of mice. The mean lifespan of P0-CNS mice was reduced by 50% compared with the other lines of mice, which had mortality rates similar to those of 
WT (n = 30 WT, 40 PLP-null, 40 PLP/P0-CNS, and 30 P0-CNS mice).P0 IN CNS MYELIN • YIN ET AL. 473
APP swellings were abundant in the cortices from the P0-CNS 
(Fig. 5 D) and PLP-null (Fig. 5 B) mice. The density of these 
swellings was greater in P0-CNS cortices than in PLP-null cor-
tices and thus correlated with the more severe neurological phe-
notype and reduced lifespan. A small but statistically signifi  cant 
increase in APP swellings was detected in P30 P0-CNS cortices 
when compared with the other three lines. Compared with   PLP-
null cortices, P0-CNS cortices contained approximately twice 
the number of axonal swellings at 3 and 6 mo of age and over 
three times the number at 1 yr.
We confi  rmed the identifi  cation of APP-positive ovoids as 
myelinated axonal swellings using postembedding electron mi-
croscopic immunocytochemistry (Fig. 5 E). Transmission EM 
detected a dramatic increase in the number of organelle-fi  lled 
axonal swellings in the cerebral cortex from 1-yr-old P0-CNS 
cortices (Figs. 5, G–I). As described in PLP-null mice (Griffi  ths 
et al., 1998; Edgar et al., 2004), APP-positive swellings occurred 
predominantly at distal paranodes. To determine whether 
axonal pathology occurred throughout the neural axis in 
P0-CNS mice, we quantifi  ed axonal swellings and axonal degen-
eration in the dorsal cervical spinal cord (corticospinal tracts) at 
6 mo of age (Fig. 6). Myelinated axonal pathology was not de-
tected in WT and PLP/P0-CNS dorsal columns (not depicted) 
but was present in PLP-null (Fig. 6 A) and P0-CNS (Fig. 6 B) 
dorsal columns. The density of swollen axons and myelinated 
axons undergoing Wallerian degeneration (Fig. 6 C) was three 
times greater in P0-CNS than in PLP-null mice. These and data 
not shown detected axon ovoids in the optic nerves, dienceph-
alons, and brain stems of P0-CNS mice.
The data described in the previous paragraph indicate that 
replacement of PLP by P0 either accelerates the formation 
paranodal axonal ovoids or increases the number of axo-
nal ovoids formed. Because axonal ovoids occur at paranodal 
regions, we investigated whether P0-CNS mice have greater 
Figure 5.  Axonal pathology and APP accu-
mulation in P0-CNS mice. (A–D) Cerebral cor-
tex sections from 12-mo-old WT (A), PLP-null 
(B), PLP/P0-CNS (C), and P0-CNS (D) mice 
stained with APP antibodies. APP-  positive 
ovoids are prominent in P0-CNS and present in 
PLP-null sections. (E) Electron microscopic immuno-
cytochemistry identiﬁ   ed these APP-positive 
ovoids as swollen axons. (F) Quantiﬁ  cation of 
APP ovoid density at 1, 3, 6, and 12 mo of 
age. At 3 mo, APP ovoids were present in 
P0-CNS mice but not in the other lines of mice. 
APP-positive ovoids progressively increased at 
3, 6, and 12 mo of age in P0-CNS sections 
and remained at low levels in WT and 
PLP/P0-CNS sections. APP-positive ovoids in 
PLP-null mice were detected at 3 mo of age 
and increased at 6 mo of age but were signiﬁ  -
cantly less than those in P0-CNS mice. (G–I) 
Ultrastructure of axonal swellings in 12-mo 
P0-CNS cerebral cortex. Organelle-ﬁ  lled axonal 
swellings occurred throughout the cerebral cor-
tex of P0-CNS mice (G, arrows). When viewed 
in longitudinal orientation (H and I), most swell-
ings were located at distal paranodes. Data 
was analyzed by a t test. Each bar in F repre-
sents data from nine sections (three sections 
from three mice; *, P < 0.05; **, P < 0.01). 
Bars: (A–D) 200 μm; (E) 0.25 μm; (G) 5 μm; 
(H and I) 2.5 μm.JCB • VOLUME 172 • NUMBER 3 • 2006  474
nodal densities than WT and PLP-null mice. Sections from 
month-old P0-CNS and WT optic nerves were double labeled 
with antibodies specifi  c for Na
+ channels and caspr, molecules 
enriched in nodal and paranodal axolemma, respectively 
 (Einheber et al., 1997; Arroyo et al., 1999; Rasband et al., 1999). 
As described previously (Rasband et al., 1999), Na
+ channels 
were clustered between caspr-positive paranodal regions in WT 
and P0-CNS sections (Figs. 7, A and B). Quantifi  cation of Na
+ 
channel cluster density detected a 50% increase in nodes of 
  Ranvier in the P0-CNS optic nerves (Fig. 7 C). This interpreta-
tion was confi  rmed by electron microscopic examination of op-
tic nerve sections. Nodes of Ranvier were rarely detected in 
electron micrographs of WT optic nerves, consistent with long 
internodal lengths. In contrast, it was common to view short in-
ternodes in P0-CNS optic nerve (Fig. 7, D and E). In addition, 
axon organelles had begun to accumulate at distal paranodes and 
form   intra-axonal ovoids (Fig. 7 E). Nodal density was increased 
twofold in P0-CNS optic nerves when compared with WT nerves. 
Because a previous study (Edgar et al., 2004) reported similar 
internodal distances in PLP-null and WT mice, these observa-
tions establish that replacement of PLP with P0 induces a gain-
of-function mutation that inhibits longitudinal growth of 
internodal CNS myelin. This generates more paranodes, which 
cause more axonal pathology, severe neurological defi  cits, and 
early death. Although short internodes can result from demye-
lination/remyelination, we saw no evidence of macrophage-
  mediated myelin stripping or asymmetric internodal lengths 
suggestive of segmental demyelination/remyelination. Some fi  -
bers were undergoing Wallerian degeneration, in which myelin 
breakdown is secondary to axonal degeneration.
Discussion
The purpose of this study was to investigate whether the shift 
from P0 to PLP during CNS myelin evolution was related to a 
new function of myelinating CNS glia. After genetic reversal of 
this shift in mice, we conclude that PLP expression in mamma-
lian oligodendrocytes and/or CNS compact myelin has a neuro-
protective benefi  t for axons. This conclusion is based on the 
severe neurological defi  cits, signifi  cant axonal degeneration, 
and dramatically reduced lifespans of mice whose oligodendro-
cytes express P0 instead of PLP. Mice expressing both PLP and 
P0 in CNS myelin had normal lifespans and no neurological dis-
ability or axonal degeneration. Therefore, the mere presence of 
P0 in CNS myelin does not appear to be responsible for the phe-
notypes in P0-CNS mice. These data suggest that mammalian 
CNS myelination sets up an axonal dependency on glial trophic 
signals that requires PLP and that cannot be replaced by reintro-
duction of the ancestral CNS myelin protein P0.
P0 and PLP family members coevolved with myelinating 
cells in the CNS of fi  sh where P0 mediates membrane adhesion 
of compact myelin (Kirschner et al., 1989; Saavedra et al., 
1989). The earliest PLP family members are in fact more closely 
related to the alternatively spliced DM20 isoform of mamma-
lian PLP. PLP/DM20 evolved and coexisted with P0 in amphib-
ian compact CNS myelin (Yoshida and Colman, 1996). The 
positively charged 35–amino acid sequence that distinguishes 
PLP from DM20 (Nave et al., 1987) has been proposed to play 
an important role in stabilizing myelin membrane compaction 
and to permit the phenotypically silent dropout of P0 from ter-
restrial vertebrate CNS myelin (Yoshida and Colman, 1996). 
We propose an alternate and/or additional hypothesis that high-
lights a CNS axon trophic role for PLP established during oli-
godendrocyte evolution. A role for PLP in maintaining the 
integrity and long-term survival of mammalian CNS axons was 
proposed previously, based on axon ovoids and axonal degenera-
tion in the CNS of PLP-null mice (Griffi  ths et al., 1998). 
In those studies, however, it was impossible to determine whether 
the axonal degeneration was a primary effect of PLP loss or a 
secondary response caused by alterations in the periodicity 
and/or stability of PLP-defi  cient myelin. This issue is resolved in 
the current study, where the neuroprotective effect of PLP was 
uncoupled from its role in CNS myelin compaction by stabiliz-
ing compact CNS myelin with P0 protein.
Our Western blot analysis of myelin fractions isolated 
from transgenic and control mice indicated that total amounts of 
P0 and/or PLP were similar in P0-CNS, PLP/P0-CNS, and WT 
mice. When expressed with or without PLP, P0 was appropri-
ately targeted to compact myelin. When overexpressed in oligo-
dendrocytes, PLP becomes toxic and eventually kills the 
oligodendrocyte (Kagawa et al., 1994; Readhead et al., 1994). 
When overexpressed in Schwann cells, P0 is mistargeted to 
Schwann cell surface membranes and inhibits the spiral wrap-
ping of myelin, which causes amyelination and severe neuro-
logical disability (Wrabetz et al., 2000; Yin et al., 2000). 
The axon ovoids described here in P0-CNS mice are not present 
in either P0- or PLP-overexpressing mice. In addition, oligoden-
drocyte death and amyelination did not occur in P0-CNS or 
PLP/P0-CNS mice. The phenotypes and pathologies of P0-CNS 
mice result from changes in myelin protein composition and not 
from increased myelin protein dosage.
The periodicity of compact CNS and PNS myelin differs, 
and each refl  ects molecular features of PLP and P0, respectively 
(Trapp and Kidd, 2004). The extracellular domain of P0 is larger 
than that of PLP, and thus the space between the extracellular 
leafl  ets and overall periodicity of PNS myelin are each  20 Å 
greater than that found in CNS myelin. Our immunocytochemical 
Figure 6.  Myelinated axonal pathology in P0-CNS cervical spinal cord. 
(A and B) Axonal swellings (arrows) and degenerating internodes (arrow-
heads) were identiﬁ  ed in electron micrographs of the cortical spinal tract 
of 6-mo-old PLP-null (A) and P0-CNS (B) mice. (C) Axonal pathology was 
ﬁ  ve times more abundant in P0-CNS than in PLP-null mice. Error bars repre-
sent SEM. *, P < 0.001. Bar, 100 μm.P0 IN CNS MYELIN • YIN ET AL. 475
and Western blot studies demonstrate that when expressed by 
oligo dendrocytes,  P0 protein is targeted to CNS myelin. When P0 
and PLP coexist in compact mouse CNS myelin, they have the 
periodicity of CNS myelin (Fig. 3). This was unexpected, as one 
might predict that obligate P0 homophilic adhesions (Filbin et al., 
1990; D’Urso et al., 1990) would dominate putative weaker elec-
trostatic trans-binding of PLP to charged lipids (Trapp and Kidd, 
2004). Because P0 homophilic adhesion may occur by trans-
  binding between cis-linked P0 tetramers (Shapiro et al., 1996), it 
is possible that PLP interferes with P0 tetramer formation in cis. 
P0 monomers or dimers would have little effect on the periodicity 
of myelin because they cannot bind in trans. In contrast, in the 
absence of PLP, P0 tetramers would form and bind in trans, thus 
dominating the spacing of compact CNS myelin, giving it the pe-
riodicity of PNS myelin, as seen ultrastructurally and when ex-
amined by x-ray diffraction (Fig. 3). Lipid bilayer thickness and 
cytoplasmic spacing of CNS and PNS myelin are identical and 
were unchanged in P0-CNS and PLP/P0 optic nerves. P0, there-
fore, can replace but not compete with PLP as the major struc-
tural protein of CNS mammalian myelin. These observations 
support the concept that PLP evolved to serve functions unrelated 
to compact myelin formation.
How does PLP maintain axonal integrity? Although it re-
mains to be determined whether PLP plays a direct or indirect 
role, observations from the PLP-null and P0-CNS mice provide 
clues to biological mechanisms. PLP-null mice have reduced 
anterograde and retrograde axonal transport that manifest as or-
ganelle accumulations at nodes of Ranvier (Griffi  ths et al., 1998; 
Edgar et al., 2004). Mice chimeric for the X-linked PLP-null 
  allele (50% of myelin internodes lack PLP) have numerically 
50% of the axonal ovoids present in PLP-null mice (Edgar et al., 
2004). This implies that PLP facilitates paranodal axonal cyto-
skeletal organization at the level of individual myelin internodes. 
Unraveling the precise mechanism by which PLP provides tropic 
support to the axon presents a signifi  cant challenge as the axo-
nopathy evolves over several months and is likely to involve al-
tered molecular complexes that organize the axon cytoskeleton 
in paranodal regions of myelinated fi  bers. Based on the chimeric 
mouse data cited above, a generalized axonal defect or altered 
neuronal gene expression seem unlikely causes of initial axonal 
pathology in PLP-null mice. This issue is further complicated as 
a null mutation in another myelin-specifi  c protein, CNP, which 
produces axon ovoids similar in appearance to those in PLP-null 
mice. Like the P0-CNS mice, CNP-null mice have earlier and 
more extensive axonal pathology, decreased motor performance 
at earlier ages, and reduced life spans (Lappe-Siefke et al., 2003). 
Some CNP-null mice have enlarged ventricles (Lappe-Siefke 
et al., 2003), a feature not present in P0-CNS or PLP-null mice. 
Whether hydrocephalus contributes to or results from axonal 
loss in CNP-null mice remains to be determined. Ovoids are not 
the only myelin-induced axonal pathology, as axonal atrophy 
occurs in MAG-defi  cient mice (Yin et al., 1998). These changes 
also have late onset (after 6 mo), manifest in paranodal axo-
plasm, and include reduced phosphorylation and spacing of 
 neurofi  laments (Yin et al., 1998).
Because P0-CNS mice have more axonal pathology than 
PLP-null mice, the PLP–P0 shift in CNS myelin causes a gain-
of-function mutation that accelerates and/or increases focal re-
ductions in axonal transport caused by PLP loss of function. 
Immunocytochemical and electron microscopic examination of 
myelin internode length in optic nerves established that P0-CNS 
mice have shorter myelin internodes, resulting in a greater den-
sity of paranodal specializations, which increased and acceler-
ated alterations in axonal transport, formation of axonal ovoids, 
axonal degeneration, and neurological disability.
The addition of the positively charged 35–amino acid se-
quence that distinguishes PLP from DM20 (Nave et al., 1987) 
may play a crucial role in axonal trophic support, as DM20 
was unable to rescue the late-onset axonopathy in PLP-null 
mice (Stecca et al., 2000). Furthermore, it is possible that this 
35–amino acid sequence evolved solely for this function, as this 
PLP-specifi  c sequence shows no signifi  cant homology with any 
other mammalian protein. The data presented here have impor-
tant implications for human diseases of myelin, as a spectrum of 
Figure 7.  Nodal density is increased in 
P0-CNS optic nerves. Confocal microscopy of 
optic nerve sections from WT (A) and 
P0-CNS (B) mice stained for Na
+ channels 
(green) and caspr (red) to mark nodal and 
paranodal regions, respectively. When quanti-
ﬁ  ed, there was an  50% increase in number 
of nodes detected in P0-CNS nerves per confo-
cal ﬁ  eld (C; ﬁ  eld dimensions 50 × 50 × 6 μm). 
By EM, P0-CNS optic nerve axons exhibited 
very short, thin internodes (D and E), with 
some ending in elongated nodes (between 
  arrowheads in D). Abnormal intra-axonal 
  organelle accumulations were also observed 
(E, asterisks). Error bars represent SEM. Bars: 
(A and B) 10 μm; (D and E) 2 μm.JCB • VOLUME 172 • NUMBER 3 • 2006  476
neurological disabilities is associated with null mutations, 
  duplications, and various point mutations in the PLP gene 
(Seitelberger, 1995; Hodes and Dlouhy, 1996). Recent studies 
have reported axonal degeneration in individuals with PLP de-
letions or point mutations (Garbern et al., 2002). Genotype–
phenotype correlations focusing on axonal degeneration and 
point mutations may identify specifi  c regions of PLP that medi-
ate axonal survival in the human CNS. Such information may 
lead to the development of novel neuroprotective therapies 
in inherited and acquired diseases of CNS myelin, such as 
Pelizaeus- Merzbacher disease and multiple sclerosis.
Materials and methods
Generation of P0 transgenic mice
We generated transgenic mice that expressed the mouse P0 cDNA (Lemke and 
Axel, 1985) ligated to a 9.1-kb region of the mouse MBP promoter (Forghani 
et al., 2001). These mice were maintained in the animal colony as homozy-
gous animals, and they displayed no obvious behavior abnormalities. Plp-null 
mice (Klugmann et al., 1997) were crossed with homozygous mice carrying 
the MBP-P0 transgene. These mice were interbred for three generations to 
obtain mice that were PLP-null and homozygous for the MBP-P0 transgene 
(P0-CNS), as determined by genomic DNA analysis and outbreeding.
Genomic DNA analysis
DNA was prepared from tail clips by standard proteinase K/phenol chlo-
roform extraction (Haney et al., 1999). Samples were analyzed by South-
ern blot or PCR to track the P0 transgene and the Plp gene, respectively. 
For Southern blot analysis, 10 μg of tail DNA was digested with EcoRI 
overnight and then separated on 1% agarose gels. Gels were blotted and 
then probed with a random primed 1.8-kb P0 probe (Lemke and Axel, 
1985). WT DNA contained four bands, and additional novel bands 
were found with the P0 transgene, most prominently a diagnostic 1.8-kb 
  fragment. The PLP-null mutation was analyzed by PCR, which generated a 
620-bp fragment from WT DNA and a 542-bp fragment from PLP-null DNA. 
The PCR program was 94°C × 3 min; 40 cycles of 94°C × 30 s; 55°C × 
30 s; 72°C × 30 s; and 72°C × 7 min. The PCR primers used were 5′-A  C  G    A-
G  C  A  G  T  G  A  G  A  G  T  T  G  G  G  T  -3′ and 5′-A  G  T  C  T  G  T  T  T  T  G  C  G  G  C  T  G  A  C  T  -3′.
RNA expression
Total RNA was prepared from P60 brains using the RNAgents total RNA 
isolation system (Promega). 5-μg samples were separated on 1% agarose 
gels and probed with P0 or PLP cDNA as described previously (Trapp et al., 
1988; Kidd et al., 1990).
Protein expression
Myelin was prepared from homogenates of P60 brains from WT, PLP-null, 
PLP/P0-CNS, and P0-CNS mice according to established procedures (Norton 
and Poduslo, 1973). In brief, brains were homogenized in 0.32 M sucrose 
and myelin was prepared by differential and gradient centrifugation as a frac-
tion that ﬂ  oats on 0.88 M sucrose. This fraction was osmotically shocked and 
centrifuged. Samples were analyzed on 12% polyacrylamide gels and stained 
(10 μg of protein) with Coomassie blue or blotted (2 μg of protein) for Western 
analysis with PLP/DM20 antibody (clone AA3; a gift from S. Pfeiffer, University 
of Connecticut Health Science Center, Farmington, CT), P0 antibody (Trapp 
et al., 1981), MAG antibody (a gift from R. Quarles, National Institutes of 
Health, Bethesda, MD), CNP, or MBP antibodies (Sternberger Monoclonals).
Motor function and mortality
To access motor function, we used the rota-rod test as described previously 
(Grifﬁ  ths et al., 1998). Five mice from each strain were tested at 3, 6, and 
12 mo of age. All mice were placed on the roller at the initial speed of 
2 rpm. The speed was continuously increased over a period of 5 min to a 
ﬁ  nal rate of 20 rpm. The time each mouse remained on the roller was 
  recorded, and differences between strains were determined by performing 
a t test. A Kaplan-Meier analysis of mortality was conducted for a minimum 
of 30 mice from each strain.
Immunocytochemistry
WT, PLP-null, PLP/P0-CNS, and P0-CNS mice were perfused with 4% para-
formaldehyde and 0.08 M Sorenson’s phosphate buffer. Brains were 
  removed, immersion ﬁ  xed overnight, cryoprotected, frozen, and sectioned 
(30 μm thick) on a sliding microtome. Free-ﬂ  oating sections were treated 
with PBS containing 3% normal goat serum and 1% Triton X-100 for 1 h 
at room temperature. Sections were incubated overnight at 4°C with 
PLP/DM20 antibody (1:100) or P0 antibody (1:800) in PBS containing 1% 
normal goat serum/0.01% Triton X-100. Sections were developed with the 
avidin biotin complex kit (Vector Laboratories) and diaminobenzidine as 
described previously (Trapp et al., 1997). Sections were photographed in 
a photomicroscope (Axiophot; Carl Zeiss MicroImaging, Inc.) with stan-
dard 2.5–20× dry lenses using a Magnaﬁ  re (Optronics) digital camera 
and software. For analysis of APP accumulation, three mice from each 
strain were processed at 1, 3, 6, and 12 mo of age. Sections were immuno-
stained with APP antibodies (Zymed Laboratories) as described above. 
The density of APP-positive axonal swellings was quantiﬁ  ed in three sec-
tions from each mouse at all ages. Differences in APP densities were deter-
mined by t test. To identify APP-positive structures as axonal swellings, 
several APP-stained 30-μm sections from P0-CNS mice were processed for 
EM as described previously (Trapp and Quarles, 1984). Sections were 
viewed and photographed in an electron microscope (CM-100; Phillips). 
Light and electron microscope images were prepared for publication using 
Photoshop 7.0 software (Adobe).
The distribution of P0 protein was also determined at the ultrastruc-
tural level. P30 mice were perfused with 2.5% glutaraldehyde, 4% para-
formaldehyde, and 0.08 M Sorensen’s phosphate buffer. The ventral 
cervical spinal cord was removed and inﬁ  ltrated with 30% polyvinlpyro-
lidine and 2.3 M sucrose. The tissue was cut in a Ultracut S ultracryomicro-
tome (Reichert) maintained at −110°C. Sections were placed on carbon- 
and formvar-coated grids and immunostained with P0 antibodies and 
immunogold procedures as described previously (Trapp et al., 1995). 
  Sections were examined in an electron microscope.
EM
Three WT, PLP-null, PLP/P0-CNS, and P0-CNS mice were perfused with 2.5% 
glutaraldehyde, 4% paraformaldehyde, and 0.08 M Sorensen’s phosphate 
buffer at 1, 3, 6, and 12 mo of age. Optic nerves, coronal slices of cerebral 
cortex, and cervical spinal cords were removed, placed in ﬁ  xative over-
night, osmicated, dehydrated, and processed to Epon 812 as described 
previously. 1-μm-thick sections were cut on glass knives in an Ultracut Eultra-
microtome, mounted on glass slides, stained with toluidine blue, and exam-
ined on a light microscope (Axiophot; Carl Zeiss MicroImaging, Inc.).
Transmission EM was performed on select Epon blocks. Sections 
were cut on a diamond knife, placed on formvar-coated grids, stained with 
uranyl acetate and lead citrate, and examined in an electron microscope. 
Optic nerve sections were obtained from all four lines and compared with 
sciatic nerves from WT mice. The periodicity of compact myelin was deter-
mined. The nature and density of axonal ovoids were determined in thin 
sections from the cerebral cortex blocks of 12-mo-old mice. In addition, the 
densities of axonal swellings and/or degenerating myelinated ﬁ  bers in the 
cortical spinal tract of 6-mo-old mice were compared by t test.
X-ray diffraction and myelin structure analysis
Sciatic and optic nerves were dissected from WT and transgenic mice that 
had been killed by decapitation. During dissection, the tissue was continu-
ally rinsed with physiological saline (154 mM NaCl and 5 mM Tris buffer, 
pH 7.4). Nerves were tied off at both ends with ﬁ  ne silk suture and inserted 
into medium-containing quartz capillary tubes, which were then sealed at 
both ends with wax. Diffraction experiments were performed as described 
previously (Avila et al., 2005) using nickel-ﬁ  ltered, single-mirror-focused 
CuKα radiation from a ﬁ  ne-line source on a 3.0-kW Rigaku x-ray generator 
(Rigaku/MSC, Inc.) operated at 40 kV by 16 or 22 mA. The x-ray diffrac-
tion patterns for each nerve were recorded ﬁ  rst for 10 min (to assess myelin 
integrity) and then for 2 h using a linear, position-sensitive detector (Molec-
ular Metrology, Inc.). The myelin periodicity was determined from the posi-
tions of the peaks (or Bragg orders) in the diffraction patterns, and the 
membrane proﬁ  les (from which the intermembrane spacings at the extracel-
lular and cytoplasmic appositions and membrane bilayer thickness were 
measured) were calculated by Fourier synthesis from the intensities of the 
Bragg orders after background subtraction (Avila et al., 2005). The proﬁ  le 
shows a periodic ﬂ  uctuation in electron density through the multilamellar 
stacking of the myelin membranes. High electron density corresponds to 
the positions of the lipid polar head groups, and the low density trough 
corresponds to the centers of the lipid hydrocarbon. The intermediate level 
of electron density between the membranes indicates protein and water in 
the spaces at the extracellular and cytoplasmic appositions. Thus, peak-
to-peak distances measured off the proﬁ  les relate to structural parameters 
of the membrane structure and its packing.P0 IN CNS MYELIN • YIN ET AL. 477
Nodal density
Density of nodes was quantiﬁ  ed in two ways in WT and P0-CNS optic 
nerves. Free-ﬂ  oating 30-μm sections of an optic nerve from each of three 
1-mo-old WT and P0-CNS mice were double immunostained as previously 
described (Yin et al., 2000) using antibodies against Na
+ channels (mouse 
pan Na
+ channel; Sigma-Aldrich) and caspr (rabbit antibody; a gift from 
J.A. Trimmer, University of California, Davis,. CA), a paranodal marker. 
Six nonadjacent areas midway between retinal and chiasmal ends of the 
optic nerve were imaged using a confocal microscope (TCS-NT; Leica) and 
software. The ﬁ  elds were collected as a z series of six slices covering 6-μm 
tissue thickness using 100× (1.3 NA) lens, and nodes were counted within 
an area 50 × 50 μm in the projected image. Z series projection was nec-
essary for interpretation, as in single slices it was sometimes difﬁ  cult to un-
equivocally interpret single spots of staining. Nodal density was also 
determined by EM. Optic nerves from three WT and three PLP/P0 mice 
aged 1 mo were embedded and mounted on Gilder 300 mesh ultrahigh 
transmission hexagonal grids (hexagonal edges were 43 μm long, and the 
grid area was 4,800 μm
2). The number of nodes in each of six grid 
squares was counted per optic nerve.
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